Advancements in Non-Invasive Tests for Liver Disease Diagnosis
Recent developments in non-invasive tests (NITs) are transforming the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals with chronic hepatitis B (CHB). Traditional liver biopsies, while effective, are invasive and costly. New imaging techniques, such as ultrasound and magnetic resonance imaging (MRI), offer safer and more accessible alternatives for assessing liver steatosis and fibrosis. These methods, including vibration-controlled transient elastography (VCTE) and controlled attenuation parameter (CAP), provide quantitative measures of liver health. Despite their promise, challenges remain in achieving consistent access and accuracy across diverse populations. 
